ReviewJAC-antimicrobial resistance2026
The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing
Review in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Ceftazidime-avibactam for multidrug and pandrug-resistant gram-negative infections in critically Ill children: a single-center pediatric ıntensive care experience.European journal of pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the impact of ceftazidime-avibactam on 30-day all-cause mortality in patients with OXA-48 producing Methods: Systematic review and meta-analysis of observational studies comparing 30-day mortality outcomes in patients infected with OXA-48 producing Results: We included five observational studies for our final analysis. None of the studies had a low risk of bias. We calculated effect estimates and used a random effects meta-analysis to generate pooled estimates. Our primary analysis found that ceftazidime-avibactam was associated with lower 30-day mortality (OR 0.46, 56/249, 22.5% versus 97/265, 36.6%, 95% CI 0.29-0.71). Our secondary analysis for the outcome of clinical success was assessable for three studies and also showed benefit (OR 3.6, 95% CI 1.85-6.9). Adjusted analyses could not be performed. Conclusions: Ceftazidime-avibactam seemed to be associated with a lower 30-day mortality and more favourable clinical outcomes compared with BAT in the treatment of OXA-48
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.